意大利Delta变异株流行期mRNA疫苗有效性与保护衰减
结果显示,第二剂后3-4周至27-30周,对感染的有效性从82%降至33%,对重症covid-19的有效性从96%降至80%。
要点
- 第二剂后27-30周,对感染有效性降至33%,对重症covid-19仍为80%。
- 高风险人群、≥80岁及60-79岁者在第二剂后27-30周对感染似无保护。
- 结果支持高风险人群、≥60岁者及医护人员在基础免疫后6个月接种加强针。
核心结论
- Delta变异株流行期,mRNA疫苗对SARS-CoV-2感染的有效性随时间显著下降,对重症covid-19的有效性下降幅度较小。
- 结果支持高风险人群、≥60岁者及医护人员在基础免疫后6个月接种加强针,并提示可考虑早于6个月及扩大加强针适用人群。
研究设计与样本
- 按接种后周时间间隔分析,采用多水平负二项模型(稳健方差估计)计算发病率比,调整性别、年龄组、疫苗品牌、优先风险类别及地区周发病率,地理区域为随机效应。
- 调整疫苗有效性按(1-IRR)×100计算,以首剂后0-14天为参照。
主要发现
- 第二剂后3-4周至27-30周,对SARS-CoV-2感染的有效性从82%(95%CI 80%至84%)降至33%(95%CI 27%至39%),P<0.001。
- 同期对重症covid-19的有效性从96%(95%CI 95%至97%)降至80%(95%CI 76%至83%),P<0.001。
- 第二剂后27-30周,高风险人群对感染的有效性为-6%(95%CI -28%至12%),≥80岁者为11%(95%CI -15%至31%),60-79岁者为2%(95%CI -11%至14%)。
关键数值与推荐
- 对感染的有效性:第二剂后3-4周82%(95%CI 80%至84%),第二剂后27-30周33%(95%CI 27%至39%)。
- 对重症covid-19的有效性:第二剂后3-4周96%(95%CI 95%至97%),第二剂后27-30周80%(95%CI 76%至83%)。
- 第二剂后27-30周对感染的有效性:高风险人群-6%(95%CI -28%至12%),≥80岁者11%(95%CI -15%至31%),60-79岁者2%(95%CI -11%至14%)。
临床怎么用
- 对高风险人群、≥60岁者及医护人员,应在基础免疫后6个月接种加强针。
- 可考虑将加强针提前至基础免疫后6个月之前,并扩大加强针适用人群。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the effectiveness of mRNA vaccines against SARS-CoV-2 infection and severe covid-19 at different time after vaccination. DESIGN: Retrospective cohort study. SETTING: Italy, 27 December 2020 to 7 November 2021. PARTICIPANTS: 33 250 344 people aged ≥16 years who received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine and did not have a previous diagnosis of SARS-CoV-2 infection. MAIN OUTCOME MEASURES: SARS-CoV-2 infection and severe covid-19 (admission to hospital or death). Data were divided by weekly time intervals after vaccination. Incidence rate ratios at different time intervals were estimated by multilevel negative binomial models with robust variance estimator. Sex, age group, brand of vaccine, priority risk category, and regional weekly incidence in the general population were included as covariates. Geographic region was included as a random effect. Adjusted vaccine effectiveness was calculated as (1-IRR)×100, where IRR=incidence rate ratio, with the time interval 0-14 days after the first dose of vaccine as the reference. RESULTS: During the epidemic phase when the delta variant was the predominant strain of the SARS-CoV-2 virus, vaccine effectiveness against SARS-CoV-2 infection significantly decreased (P<0.001) from 82% (95% confidence interval 80% to 84%) at 3-4 weeks after the second dose of vaccine to 33% (27% to 39%) at 27-30 weeks after the second dose. In the same time intervals, vaccine effectiveness against severe covid-19 also decreased (P<0.001), although to a lesser extent, from 96% (95% to 97%) to 80% (76% to 83%). High risk people (vaccine effectiveness -6%, -28% to 12%), those aged ≥80 years (11%, -15% to 31%), and those aged 60-79 years (2%, -11% to 14%) did not seem to be protected against infection at 27-30 weeks after the second dose of vaccine. CONCLUSIONS: The results support the vaccination campaigns targeting high risk people, those aged ≥60 years, and healthcare workers to receive a booster dose of vaccine six months after the primary vaccination cycle. The results also suggest that timing the booster dose earlier than six months after the primary vaccination cycle and extending the offer of the booster dose to the wider eligible population might be warranted.
引用
- Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. 2022. PMID: 35144968. doi:10.1136/bmj-2021-069052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。